Abbott Laboratories (NYSE: ABT)’s stock price has plunge by -0.20relation to previous closing price of 109.11. Nevertheless, the company has seen a -1.47% plunge in its stock price over the last five trading sessions. Forbes reported 2024-04-15 that Abbott (NYSE: ABT) will report its Q1 2024 results on Wednesday, April 17. We expect the company to post revenue of $9.9 billion and earnings of $0.95 on a per share and adjusted basis, aligning with the street expectations.
Is It Worth Investing in Abbott Laboratories (NYSE: ABT) Right Now?
Abbott Laboratories (NYSE: ABT) has a price-to-earnings ratio that is above its average at 33.34x. The stock has a 36-month beta value of 0.74. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 7 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ABT is 1.72B, and at present, short sellers hold a 0.84% of that float. On April 16, 2024, the average trading volume of ABT was 5.73M shares.
ABT’s Market Performance
ABT stock saw a decrease of -1.47% in the past week, with a monthly decline of -8.38% and a quarterly a decrease of -4.42%. The volatility ratio for the week is 1.65%, and the volatility levels for the last 30 days are 1.70% for Abbott Laboratories (ABT). The simple moving average for the last 20 days is -2.55% for ABT stock, with a simple moving average of 2.05% for the last 200 days.
Analysts’ Opinion of ABT
Morgan Stanley, on the other hand, stated in their research note that they expect to see ABT reach a price target of $112. The rating they have provided for ABT stocks is “Equal-Weight” according to the report published on May 30th, 2023.
Wolfe Research gave a rating of “Underperform” to ABT, setting the target price at $103 in the report published on April 20th of the previous year.
ABT Trading at -5.08% from the 50-Day Moving Average
After a stumble in the market that brought ABT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.48% of loss for the given period.
Volatility was left at 1.70%, however, over the last 30 days, the volatility rate increased by 1.65%, as shares sank -5.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.89% lower at present.
During the last 5 trading sessions, ABT fell by -1.47%, which changed the moving average for the period of 200-days by +1.19% in comparison to the 20-day moving average, which settled at $111.41. In addition, Abbott Laboratories saw -1.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABT starting from Salvadori Daniel Gesua Sive, who sale 963 shares at the price of $118.50 back on Mar 01 ’24. After this action, Salvadori Daniel Gesua Sive now owns 125,697 shares of Abbott Laboratories, valued at $114,116 using the latest closing price.
ALLEN HUBERT L, the EXECUTIVE VICE PRESIDENT of Abbott Laboratories, sale 853 shares at $118.50 during a trade that took place back on Mar 01 ’24, which means that ALLEN HUBERT L is holding 184,806 shares at $101,080 based on the most recent closing price.
Stock Fundamentals for ABT
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.54 for the gross margin
The net margin for Abbott Laboratories stands at 0.14. The total capital return value is set at 0.12. Equity return is now at value 15.15, with 7.72 for asset returns.
Based on Abbott Laboratories (ABT), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at 0.49. The debt to equity ratio resting at 0.39. The interest coverage ratio of the stock is 9.78.
Currently, EBITDA for the company is 10.59 billion with net debt to EBITDA at 0.88. When we switch over and look at the enterprise to sales, we see a ratio of 4.93. The receivables turnover for the company is 6.11for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
To sum up, Abbott Laboratories (ABT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
